LICENSING
With 61 significant deals executed in twelve months, 2012 became the single most successful licensing year to date for Merck.
And the company is not about to hold back. In the first two months of 2013, Merck has already announced new deals with Adimab, Lycera and Samsung Bioepsis. According to Roger Pomerantz, Worldwide Head of Licensing and Acquisitions, Merck remains busy ‘bringing together small company passion with large company power’.
Read the full article.At Merck, flexibility, innovation and creativity are at the heart of the way we work with partners around the world.
Our Licensing team works with partners to advance their science through drug discovery and development collaborations and licensing agreements that are mutually beneficial.
Our Commercial Partnerships team pursues business opportunities with partners to jointly deliver their products and ours to the marketplace.
Read more Partnership Success
If you think something you discovered might be of interest to Merck, contact one of our scientific scouts.